After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, BBIO falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of BridgeBio Pharma Inc is $10.06B. A total of 1.9 million shares were traded on the day, compared to an average of 2.86M shares.
In the most recent transaction, MCCORMICK FRANK sold 74,000 shares of BBIO for 53.16 per share on Sep 05 ’25. After the transaction, the Director now owns 83,275 company shares. In a previous transaction on Sep 05 ’25, Kumar Neil sold 40,000 shares at 53.05 per share. BBIO shares that Chief Executive Officer owns now total 875,686.
Among the insiders who sold shares, Kumar Neil disposed of 40,000 shares on Sep 04 ’25 at a per-share price of $51.34. This resulted in the Chief Executive Officer holding 895,686 shares of BBIO after the transaction. In another insider transaction, FRANK P. MCCORMICK bought 74,000 shares at $53.14 per share on Sep 05 ’25.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, BBIO has a high of $54.60 and a low of $21.72.
As of this writing, BBIO has an earnings estimate of -$0.73 per share for the current quarter. EPS was calculated based on a consensus of 4.0 estimates, with a high estimate of -$0.45 per share and a lower estimate of -$1.01. The company reported an EPS of -$1.08 in the last quarter
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. BBIO’s latest balance sheet shows that the firm has $836.66M in Cash & Short Term Investments as of fiscal 2021. There were $1.73B in debt and $135.07M in liabilities at the time. Its Book Value Per Share was -$9.35, while its Total Shareholder’s Equity was -$865.58M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BBIO is Buy with a score of 4.77.
